Figure 7.

Effects of DK-I-56-1 (DK, 10 mg/kg, IP) and dopaminergic antagonists on the exacerbation of spontaneous eye blinking in C57BL/6 mice treated with SKF 82958 (0.5 mg/kg, IP). (A) Two-way ANOVA showed that SKF 82958 significantly increased eye blinking (Main effect: F(1,22) = 31.45, p = 0.00001), while DK reduced it (Main effect: F(1,22) = 6.75, p = 0.02). A significant interaction between the two treatments was found (F(1,22) = 6.37, p = 0.02), revealing that DK significantly reduced the blinks in mice treated with SKF 82958. (B) The D₁ antagonist SCH 23390 (0.5 mg/kg, IP) also countered the elevation in eyeblinks caused by SKF 82958 (Main effect of SKF 82958: F(1,30) = 28.68, p < 0.00001; Main effect of SCH 23390: F(1,30) = 181.6, p < 0.00001; Interaction: F(1,30) = 25.10, p = 0.00002). (C) The D₂ antagonist haloperidol (HAL, 0.5 mg/kg, IP) reduced eyeblinks, but this effect did not interact with the elevation of eyeblinks induced by SKF 82958. (Main effect of SKF 82958: F(1,28) = 22.98, p = 0.00005; Main effect of HAL: F(1,28) = 25.59, p = 0.00002; Interaction: F(1,28) = 2.79, NS). ^^^^ p < 0.0001 main effect of SKF 82958 vs. saline (SAL); **** p < 0.0001 vs. mice treated with VEH and SAL; ^## p = 0.001 and ^#### p < 0.0001 vs. mice treated with VEH. n = 6–8/group. For further details, see text.